Fibrodysplasia Ossificans Progressiva

Overview

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, usually sporadic autosomal-dominant genetic disorder in which a gain-of-function variant in the ACVR1 gene causes bone to form in muscles, tendons, ligaments, and other soft tissues—a process called heterotopic ossification (HO). Most people with classic FOP have the same ACVR1 p.R206H variant and are born with malformed great toes; painful inflammatory “flare-ups” can precede new bone formation. GeneReviews: Fibrodysplasia Ossificans Progressiva FOP progressively restricts joint movement, and bone affecting the jaw, spine, hips, or chest can impair eating, walking, and breathing; the disease is irreversible and can shorten survival through cardiorespiratory complications. Garetosmab BLA priority-review announcement

Current care combines prevention of avoidable tissue injury, management of flare-ups and pain, mobility and respiratory support, dental and anesthesia planning, and monitoring for complications. Procedures that can injure soft tissue—including biopsies, nonessential surgery, intramuscular injections, and forceful passive range-of-motion therapy—can provoke HO and are generally avoided. GeneReviews: Fibrodysplasia Ossificans Progressiva In the United States, palovarotene (Sohonos) is approved to reduce the volume of newly forming HO in eligible patients, but it does not remove bone that has already formed or correct the underlying mutation. FDA approval of Sohonos

Scope of Recent Research (2020–present)

Research since 2020 has been unusually productive for such a small patient population: investigators have advanced pathway-targeted drugs into late-stage trials while developing genetic strategies that directly suppress the mutant ACVR1 signal. The central questions are how best to stop Activin A–driven abnormal bone signaling, prevent inflammation-linked flare-ups from becoming permanent bone, and selectively silence or replace the mutant allele without disrupting normal skeletal biology. Recent progress in FOP drug development The field is approaching stronger prevention of future HO, especially after positive garetosmab results, but it is not yet close to a demonstrated curative therapy that safely corrects disease throughout the body and reverses existing skeletal damage. Garetosmab phase 2 trial

Major Breakthroughs and Emerging Therapies

The most clinically advanced strategy is blocking Activin A, a signaling protein that abnormally activates mutant ACVR1 and drives bone formation in FOP. In the randomized phase 2 LUMINA-1 trial, garetosmab, an Activin A–neutralizing antibody, did not meet its initial PET-CT lesion-activity endpoint during the blinded period, but it markedly reduced formation of new HO lesions after placebo-treated participants crossed over to treatment. Garetosmab phase 2 trial This mechanistic validation led to the phase 3 OPTIMA study, in which both tested doses reportedly reduced the number of new lesions by approximately 90% or more versus placebo at 56 weeks. Garetosmab BLA priority-review announcement As of August 8, 2026, garetosmab remains investigational in the United States: the FDA accepted its biologics application for priority review, with an action date in August 2026. FDA orphan-drug record for garetosmab

Palovarotene is the first approved disease-modifying therapy for FOP, although it is not a cure. It is an oral retinoic-acid receptor-gamma agonist intended to reduce new HO formation by interfering with the cartilage-forming stage that precedes abnormal bone. FDA approval of Sohonos In the single-arm phase 3 MOVE study, annualized new HO volume was lower in treated participants than in an untreated natural-history comparator group, at 9.4 versus 20.3 cm³ per year. FDA Drug Trials Snapshot: Sohonos Its limitations are important: the study used an external rather than randomized control group, and retinoid-related toxicity—including skin and mucosal effects, bone effects, and concern about premature growth-plate closure in growing children—requires careful monitoring. FDA Drug Trials Snapshot: Sohonos

Gene-directed approaches are the clearest conceptual route toward a cure because classic FOP is caused by one dominant mutant allele. In mouse models and patient-derived induced pluripotent stem cells, researchers used adeno-associated virus (AAV) vectors to combine allele-selective artificial microRNA silencing of mutant ACVR1 with expression of a codon-modified normal ACVR1 copy; this suppressed abnormal Activin A signaling and greatly reduced trauma-induced HO in mice. AAV gene delivery suppresses FOP ossification A follow-on study added microRNAs against both Activin A and mutant ACVR1 and engineered liver-detargeting control into the vector, again reducing HO in a mouse model. AAV-mediated targeting of Activin A–ACVR1 signaling These are promising preclinical results, not human gene-therapy trials.

RNA therapeutics are also emerging. A 2026 preclinical report described allele-selective small interfering RNA (siRNA) against ACVR1 p.R206H, including a dual strategy that also targets the inflammatory mediator IL-1β; lipid-conjugated siRNA reduced HO in a mouse FOP model and improved delivery to muscle. Precision RNAi for FOP This work is particularly relevant because it attempts to preserve normal wild-type ACVR1 while reducing the disease-causing allele, but it remains experimental and has not established safety, dosing durability, or clinical benefit in people.

Clinical Trials and Experimental Approaches

Palovarotene is approved in the United States for females aged eight years and older and males aged ten years and older, based principally on the phase 3 MOVE study and a natural-history comparison cohort. FDA Drug Trials Snapshot: Sohonos Its approval represents a meaningful preventive advance, but the indication is reduction of new HO volume rather than reversal of established disease. FDA approval of Sohonos

Regeneron’s garetosmab completed the 63-participant, randomized, placebo-controlled phase 3 OPTIMA trial in adults with active FOP. The company reported substantial reductions in both the number and volume of new HO lesions, while common adverse reactions included nosebleeds, increased hair growth, abscesses, and acne. Garetosmab BLA priority-review announcement The trial’s primary completion date was July 17, 2025, and a pediatric phase 3 program, OPTIMA 2, was planned for later in 2026. ClinicalTrials.gov: OPTIMA

Not every direct-pathway approach has succeeded. Ipsen’s pivotal phase 2 FALKON trial of fidrisertib, an oral ALK2/ACVR1 kinase inhibitor, enrolled 113 patients aged five years and older but did not meet its primary endpoint of reducing new HO volume versus placebo; Ipsen closed the study in December 2025, despite reporting no new safety concern. Ipsen FALKON trial update

Methodologies and Scientific Approaches

FOP research combines human natural-history studies, whole-body low-dose CT measurement of HO volume, positron-emission tomography for early bone activity, patient-derived cells, and genetically engineered mouse models. The first prospective international 36-month natural-history study followed 114 people with classic FOP and documented that flare-ups are common but do not uniformly yield radiographically detectable new HO, illustrating why both symptom and imaging endpoints are needed. Prospective global FOP natural-history study Garetosmab trials similarly used whole-body CT and PET-CT to quantify new and active lesions. Garetosmab phase 2 trial

At the laboratory level, researchers focus on fibro-adipogenic progenitors—muscle-resident repair cells that can be redirected by mutant ACVR1 toward cartilage and bone—and test whether therapies restore normal muscle repair without blocking healthy bone maintenance. Cellular and molecular mechanisms of FOP HO AAV vectors, engineered microRNAs, chemically modified siRNAs, and patient-derived induced pluripotent stem cells are being used to test allele selectivity, tissue targeting, and suppression of abnormal SMAD signaling before human translation. AAV gene delivery suppresses FOP ossification

Leading Institutions and Funding

The field is driven by multinational collaborations linking specialist clinical centers with industry. University of Pennsylvania investigators, including long-standing FOP researchers Frederick Kaplan and Mona Al Mukaddam, participated in the garetosmab clinical program alongside centers in Europe and North America; Mayo Clinic, Amsterdam UMC, University of Oxford–associated investigators, and other international sites have also contributed to natural-history and therapeutic studies. Garetosmab phase 2 trial Prospective global FOP natural-history study

Regeneron is advancing garetosmab and supporting the OPTIMA program, while Ipsen developed palovarotene and conducted the fidrisertib FALKON trial. Garetosmab BLA priority-review announcement Ipsen FALKON trial update Patient organizations also play an outsized role: the International FOP Association’s Competitive Research Grant program was established to accelerate translational research and therapeutic development for FOP. IFOPA Competitive Research Grant Program

Strengths, Limitations, and Challenges

A major strength of current research is convergence on a biologically validated disease axis: mutant ACVR1, Activin A, inflammation, cartilage formation, and ectopic bone. Garetosmab’s phase 3 lesion-prevention results provide the strongest recent clinical evidence that blocking an upstream driver can substantially alter formation of new HO. Garetosmab BLA priority-review announcement Palovarotene also established that prospective suppression of new HO is clinically achievable. FDA Drug Trials Snapshot: Sohonos

However, prevention is not reversal. Existing HO is permanent, late-stage disease leaves little recoverable movement, and an ultra-rare condition makes trials small, heterogeneous, and dependent on imaging or natural-history comparators. Prospective global FOP natural-history study Safety is especially difficult because Activin A and ACVR1 have normal roles in tissue biology, palovarotene can affect growing skeletons, and systemic genetic therapies must reach vulnerable connective-tissue progenitors without unwanted long-term effects. FDA approval of Sohonos AAV-mediated targeting of Activin A–ACVR1 signaling The fidrisertib failure also shows that a strong mechanistic rationale and selective kinase inhibition do not guarantee clinical efficacy. Ipsen FALKON trial update

Outlook and Future Directions

The near-term outlook is for better prevention rather than a cure: the key milestone immediately ahead is the FDA’s August 2026 decision on garetosmab for adults, followed by rigorous pediatric testing and longer-term evaluation of function, respiratory outcomes, and cumulative safety. Garetosmab BLA priority-review announcement A true cure will likely require safe body-wide, durable correction or silencing of mutant ACVR1, ideally combined with ways to prevent or repair the consequences of existing HO; AAV and allele-selective RNA programs are scientifically credible early steps, but they remain preclinical. AAV gene delivery suppresses FOP ossification Precision RNAi for FOP

References

• GeneReviews: Fibrodysplasia Ossificans Progressiva — Akesson and Savarirayan, 2024.
• FDA approval of Sohonos — U.S. Food and Drug Administration, 2023.
• FDA Drug Trials Snapshot: Sohonos — U.S. Food and Drug Administration, 2023.
• Garetosmab phase 2 trial — Di Rocco et al., Nature Medicine, 2023.
• Garetosmab BLA priority-review announcement — Regeneron Pharmaceuticals, 2026.
• FDA orphan-drug record for garetosmab — U.S. Food and Drug Administration, 2026.
• ClinicalTrials.gov: OPTIMA — U.S. National Library of Medicine, 2026.
• Ipsen FALKON trial update — Ipsen, 2025.
• Recent progress in FOP drug development — Meng, Wang, and Hao, Molecular and Cellular Biochemistry, 2022.
• AAV gene delivery suppresses FOP ossification — Yang et al., Nature Communications, 2022.
• AAV-mediated targeting of Activin A–ACVR1 signaling — Yang et al., Molecular Therapy: Nucleic Acids, 2023.
• Precision RNAi for FOP — UMass Chan Medical School collaborators, 2026.
• Prospective global FOP natural-history study — Pignolo et al., Genetics in Medicine, 2022.
• Cellular and molecular mechanisms of FOP HO — Sorkin and colleagues, Cells, 2024.
• IFOPA Competitive Research Grant Program — International FOP Association, 2016.